TrialAlimentary pharmacology & therapeutics2024

Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials.

Maria Buti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.